.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
Interview: The Imaging Wire highlights MASAI findings
Brian Casey of The Imaging Wire interviews researcher Jessie Gommers on the latest results from the MASAI randomised controlled trial in breast cancer AI.
.png)
ScreenPoint Medical's founders honored
Nico Karssemeijer and Sir Michael Brady honored for their notable achievements and contributions to healthcare and the sciences.
MASAI RCT: 12% reduction in interval cancer rate using Transpara
New research highlights Transpara Detection ‘s impact on the MASAI randomized controlled trial’s final endpoint: interval cancers.
.png)
ScreenPoint Medical and Ferrum Health partner to offer Transpara Breast AI through Ferrum’s AI Governance Suite
Ferrum Health will offer Transpara solutions through its Model Hub, helping radiologists increase breast cancer detection and improve their workflow
.png)
Our Top 5 in 2025
ScreenPoint Medical's top news, articles, blogs, and perspective from 2025.
What studies showed us about Transpara in 2025
Highlights from peer-reviewed research on Transpara Breast AI published in 2025 on increasing breast cancer detection and reducing radiology workload.